Table 2.

Chemotherapy for hepatocellular carcinoma with portal vein tumor thrombus

Lead author	Yr	n	Location of tumor thrombus	Route	treatment	Response rate (CR+PR) (%)	Median survival time (mo)
Systemic chemotherapy
Okada S et al[26]	1992	22	Vp4	S	Tegaful, doxorubicin, MTX, CDDP, 5-FU, etc.	-	3.9
Low dose CDDP & 5-FU					Low dose CDDP & 5-FU
Ando E et al[28]	1996	9	Vp4	R	CDDP, 5-FU	44	9.2
Itamoto T et al[29]	2002	7	Vp3, 4	R	5-FU + CDDP	33	7.5
Yamasaki T et al[30]	2002	6	Vp3, 4	R	CDDP, 5-FU/+ leucovorin	0	4.5
Interferon & 5-FU
Patt YZ et al[32]	1993	291	-	S	5-FU + Interferon-α	22	-
Urabe T et al[33]	1998	16	Vp3, 4	R	MTX, 5-FU, cisplatin, Interferon-α	46.7	7
Kaneko S et al[34]	2002	34	Vp3, 4	R	5-FU, CDDP, MTX, + Interferon-α + Leucovorin	44	11 (CR + PR)
							3.5 (SD + PD)
Sakon M et al[35]	2002	8	Vp3, 4	R	5-FU + Interferon-α	63	-
Ota H et al[36]	2005	55	Vp3, 4	R	5-FU + Interferon-α	43.6	11.8
Obi S et al[37]	2005	116	Vp3, 4	R	5-FU + Interferon-α	52	6.9

¹Including all patients with HCC. S: Systemic chemotherapy; R: Regional chemotherapy via hepatic artery; MTX: methotrexate; CDDP: cisplatin.